Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Net Income towards Common Stockholders (2016 - 2025)

International Stem Cell (ISCO) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with $91000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 46.77% to $91000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was -$115000.0, a 84.35% increase, with the full-year FY2024 number at -$213000.0, up 73.44% from a year prior.
  • Net Income towards Common Stockholders was $91000.0 for Q2 2025 at International Stem Cell, up from -$218000.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $91000.0 in Q2 2025 to a low of -$641000.0 in Q3 2021.
  • A 5-year average of -$210666.7 and a median of -$172500.0 in 2023 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 20500.0% in 2023, then surged 115.05% in 2024.
  • International Stem Cell's Net Income towards Common Stockholders stood at -$362000.0 in 2021, then soared by 107.73% to $28000.0 in 2022, then tumbled by 1735.71% to -$458000.0 in 2023, then skyrocketed by 102.62% to $12000.0 in 2024, then skyrocketed by 658.33% to $91000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Net Income towards Common Stockholders are $91000.0 (Q2 2025), -$218000.0 (Q1 2025), and $12000.0 (Q4 2024).